Wockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of global antibiotic trial for innovations like WCK5222 and WCK4873.
Related Keywords
Japan , United States , India , China , America , , Drugmaker Wockhardt , North America , Wockhardt , Debt , Drug Trial , Clinical Trials , Wck5222 , Antibiotic ,
vimarsana.com © 2020. All Rights Reserved.